Skip to content
BiologicalX

Comparison

Armodafinil vs Testosterone

Side-by-side of Armodafinil and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Armodafinil

  • FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
  • R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
  • Schedule IV controlled in the US; prescription-only globally
  • Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
  • Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
  • Side-effect profile and dermatologic risk warnings mirror modafinil

Testosterone

  • Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
  • Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
  • TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
  • Schedule III controlled substance in US; WADA banned in sport
  • Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
  • Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect

Side-by-side

Attribute Armodafinil Testosterone
Category pharmaceutical hormone
Also known as Nuvigil, R-modafinil, (R)-(-)-modafinil TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim
Half-life (hr) 15 192
Typical dose (mg) 150 150
Dosing frequency daily, morning weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet)
Routes oral intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral
Onset (hr) 1 24
Peak (hr) 3 72
Molecular weight 273.35 288.42
Molecular formula C15H15NO2S C19H28O2
Mechanism Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects.
Legal status Schedule IV (US); prescription-only globally; not a supplement Schedule III controlled substance (US); WADA banned
WADA status banned banned
DEA / Rx Schedule IV Schedule III
Pregnancy Not recommended Category X; contraindicated in pregnancy (virilizing effect on female fetus)
CAS 112111-43-0 58-22-0
PubChem CID 9148206 6013
Wikidata Q4791953 Q150726

Safety profile

Armodafinil

Common side effects

  • headache
  • nausea
  • dizziness
  • anxiety
  • insomnia (with later-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)

Testosterone

Common side effects

  • erythrocytosis
  • acne
  • oily skin
  • fluid retention
  • increased body hair
  • fertility suppression
  • injection-site reactions

Contraindications

  • active prostate cancer
  • active breast cancer
  • untreated severe sleep apnea
  • untreated severe BPH
  • uncontrolled heart failure
  • polycythemia at baseline

Interactions

  • warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
  • insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
  • 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
  • aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)

Which Should You Take?

Armodafinil and Testosterone score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.

  • If your priority is wakefulness, pick Armodafinil.
  • If your priority is focus or working memory, pick Armodafinil.
  • If your priority is hormonal optimization, pick Testosterone.
  • If your priority is sexual function, pick Testosterone.

Edge case: Testosterone is contraindicated in pregnancy; Armodafinil is the safer pick if that applies.

Default choice: either is defensible. Armodafinil edges out on goal breadth + legal accessibility; Testosterone is the right call if your priority sits in the goals listed above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Armodafinil and Testosterone?

Armodafinil and Testosterone differ in category (pharmaceutical vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Armodafinil or Testosterone?

Armodafinil half-life is 15 hours; Testosterone half-life is 192 hours.

Can you stack Armodafinil with Testosterone?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper